This is a preview of subscription content, log in via an institution to check access.
Notes
This represents a "disinvestment decision" where the incremental health benefit from using colistimethate sodium DPI is negative but the cost savings from its use may be used generate additional health elsewhere within the NHS.
Reference
Tappenden P, et al. The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. PharmacoEconomics : 13 Dec 2013. Available from: URL: http://dx.doi.org/10.1007/s40273-013-0122-x
Rights and permissions
About this article
Cite this article
DPI antibacterials for P. aeruginosa in CF value for money?. PharmacoEcon Outcomes News 694, 4 (2014). https://doi.org/10.1007/s40274-014-0964-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-0964-2